Skip to content

Released Nov 10, 2025, before the open

10-Q filed Nov 10, 2025, 41 days after period end · 0001764013-25-000149

Q2 2026 · 10-Q
Revenue—
Net Income-$126.50MN/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.73N/M vs Q2 2025N/M vs Q1 2026
Operating Cash Flowderived-$102,515,000N/M
Free Cash Flowderived-$102,515,000N/M

What the release said

The release

Same quarter

MetricQ2 2026Q2 2025Q2 2024Q2 2023
Net Income-$126.50M-$109.12M-$58.66M-$47.93M
EPS Diluted-$0.73-$0.74-$0.45-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR